Befotertinib

SKU: orb1303551

Description

Befotertinib (D-0316) is a third-generation EGFR tyrosine kinase inhibitor designed to target the T790M resistance mutation. It is a research compound used in preclinical studies, including in vitro cellular assays and in vivo models, for non-small cell lung cancer (NSCLC).

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1835667-63-4
• MW: 567.61
• Purity: 99.83%
• Formula: C₂₉H₃₂F₃N₇O₂
• SMILES: COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(CC(F)(F)F)c2ccccc12
• Target: EGFR
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.52 mM);DMSO:60 mg/mL (105.71 mM)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

D 0316, D0316, D-0316, Befotertinib, cancer, EGFR, Epidermal growth factor receptor, ErbB-1, Inhibitor, HER1, inhibit, kinase, non-small, NSCLC, lung, tyrosine

Compound Identifiers

PubChem CID

130412842